September 16, 2022
Life Sciences
  • A New York Times article provides insight into the Food and Drug Administration (FDA) prescription drug user fee debate as Congress works toward finalizing a bill by September 30. While critics of the program say it gives the drug and medical device industry too much influence over a process meant to ensure those products are safe and effective, advocates point out that the program has accelerated the process of getting life-saving drugs to the market and now accounts for three-fourths of the FDA’s drug division budget. (Article here)